FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Marc Bourlière

Research Profile

Disorders

Chemicals & Drugs

Living Beings

Physiology

Genotype

Procedures

Drug Therapy, Combination

Concepts & Ideas

Geographic Areas

France

Anatomy

Livers

Co-author Network

Publications

TOP 3
Marc Bourlière; Hélène Fontaine; Christophe Hézode; Stanislas Pol; Astrid Wendt; Jean-Pierre Bronowicki
How to optimize HCV therapy in genotype 1 patients with cirrhosis.
Sofiane Mohamed; Daniel Olive; Denis Ouzan; Guillaume Pénaranda; Audrey Raimondo; Sophie Ravet; Marc Bourlière; Claire Camus; Patrick Dukan; Hacène Khiri; Philippe Halfon
Dried blood spot sampling for hepatitis B virus serology and molecular testing.
Claire Wartelle-Bladou; Marc Bourlière; G Le Folgoc; Laurence Lecomte
Hepatitis C therapy in non-genotype 1 patients: the near future.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Marc Bourlière (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Marc Bourlière; Hélène Fontaine; Christophe Hézode; Stanislas Pol; Astrid Wendt; Jean-Pierre Bronowicki
How to optimize HCV therapy in genotype 1 patients with cirrhosis.
Liver international : official journal of the International Association for the Study of the Liver 2013;33 Suppl 1():46-55.
2013: Sofiane Mohamed; Daniel Olive; Denis Ouzan; Guillaume Pénaranda; Audrey Raimondo; Sophie Ravet; Marc Bourlière; Claire Camus; Patrick Dukan; Hacène Khiri; Philippe Halfon
Dried blood spot sampling for hepatitis B virus serology and molecular testing.
PloS one 2013;8(4):e61077.
2012: Claire Wartelle-Bladou; Marc Bourlière; G Le Folgoc; Laurence Lecomte
Hepatitis C therapy in non-genotype 1 patients: the near future.
Journal of viral hepatitis 2012;19(8):525-36.
2012: Philippe Halfon; Asma Kahloun; Hacène Khiri; Agnès Martineau; Lou Naldi; Valerie Oulès; Denis Ouzan; Guillaume Pénaranda; Nolwenn Amrani; Paul Castellani; Lise Fanteria; Marc Bourlière
Detection of IL28B SNP DNA from buccal epithelial cells, small amounts of serum, and dried blood spots.
PloS one 2012;7(3):e33000.
2012: Marc Bourlière; Michel Doffoël; Francis Fagnani; Patrick Marcellin; Denis Ouzan; Jean-Michel Pawlotsky; Alexandrina Pinta; Michel Rosenheim; Stéphanie Rouanet; Laurence Salomon; Muriel Vray
Pegylated interferon-α2a plus ribavirin for chronic hepatitis C in a real-life setting: the Hepatys French cohort (2003-2007).
Antiviral therapy 2012;17(1):101-10.
2011: Marc Bourlière; Xavier Adhoute; Souad Benali; Asma Khaloun; Valérie Oules; Isabelle Portal; Claire Wartelle-Bladou; Paul Castellani
Chronic hepatitis C: treatments of the future.
Clinics and research in hepatology and gastroenterology 2011;35 Suppl 2():S84-95.
2010: Bertrand Nalpas; Roubila Lavialle-Meziani; Sabine Plancoulaine; Emmanuelle Jouanguy; Antoine Nalpas; Mona Munteanu; Frédéric Charlotte; Brigitte Ranque; Etienne Patin; Simon Heath; Hélène Fontaine; Anaïs Vallet-Pichard; Dominique Pontoire; Marc Bourlière; Jean-Laurent Casanova; Mark Lathrop; Christian Bréchot; Thierry Poynard; Fumihiko MATSUDA; Stanislas Pol; Laurent Abel
Interferon gamma receptor 2 gene variants are associated with liver fibrosis in patients with chronic hepatitis C infection.
Gut 2010;59(8):1120-6.
2009: Philippe Halfon; Guillaume Pénaranda; Fabrice CARRAT; P Bedossa; Marc Bourlière; Denis Ouzan; C Renou; Albert Tran; Eric Rosenthal; C Wartelle; P Delasalle; P Cacoub
Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients.
Alimentary pharmacology & therapeutics 2009;30(1):61-70.
2009: Christophe Hézode; Nicole Forestier; Geoffrey Dusheiko; Peter Ferenci; Stanislas Pol; Tobias Goeser; Jean-Pierre Bronowicki; Marc Bourlière; SHAHIN GHARAKHANIAN; Leif Bengtsson; Lindsay McNair; Shelley George; Tara Kieffer; Ann Kwong; Robert S Kauffman; John Alam; Jean-Michel Pawlotsky; Stefan Zeuzem
Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.
The New England journal of medicine 2009;360(18):1839-50.
2008: Christophe Renou; Jean-François Cadranel; Alexandre Pariente; Guillaume Pénaranda; Marc Bourlière; Philippe Halfon; Jean-Pierre Igual; Abdelouahid Harafa; Pierre Muller; Jean-Jacques Bertrand; René Laugier
Adefovir combined with hepatitis C virus treatment may prevent hepatitis B reactivation after hepatitis C virus eradication in hepatitis B and C virus carriers.
European journal of gastroenterology & hepatology 2008;20(12):1235-7.
2008: Paul Calès; Victor de Ledinghen; Philippe Halfon; Yannick Bacq; Vincent Leroy; Jérôme Boursier; Juliette Foucher; Marc Bourlière; Anne De Muret; Nathalie Sturm; Gilles Hunault; Frédéric Oberti
Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C.
Liver international : official journal of the International Association for the Study of the Liver 2008;28(10):1352-62.
2008: Hélène Castel; Laurence Bocket; Catherine Tamalet; Marc Bourlière; Yazdan Yazdanpanah
How should chronic hepatitis B virus infection be managed in HIV-hepatitis B virus-coinfected patients not eligible for concomitant antiretroviral therapy?
AIDS (London, England) 2008;22(18):2551-2.
2008: Vincent Leroy; Philippe Halfon; Yannick Bacq; Jérôme Boursier; Marie Christine Rousselet; Marc Bourlière; Anne De Muret; Nathalie Sturm; Gilles Hunault; Guillaume Penaranda; Marie-Claude Bréchot; Candice Trocme; Paul Calès
Diagnostic accuracy, reproducibility and robustness of fibrosis blood tests in chronic hepatitis C: a meta-analysis with individual data.
Clinical biochemistry 2008;41(16-17):1368-76.
2008: Philippe Halfon; Marc Bourlière; Hacène Khiri; Guillaume Pénaranda; Agnes Martineau; Valérie Oulès; Jérôme Courcambeck; Patrick Philibert
Mutation rate in hepatitis C virus NS3 protease is not influenced by HIV-1 protease inhibitor therapy.
AIDS (London, England) 2008;22(13):1694-6.
2008: Philippe Halfon; Marc Bourlière; Denis Ouzan; Damien Sène; David Saadoun; Hacène Khiri; Guillaume Pénaranda; Agnes Martineau; Valérie Oulès; Patrice Cacoub
Occult hepatitis C virus infection revisited with ultrasensitive real-time PCR assay.
Journal of clinical microbiology 2008;46(6):2106-8.
2007: Marc Bourlière; Jean Charles Duclos-Vallée; Stanislas Pol
[Liver and antiretrovirals: hepatotoxicity, steatosis and monitoring of patients with liver disease].
Gastroentérologie clinique et biologique 2007;31(10):895-905.
2007: Thierry Poynard; Philippe Halfon; Laurent Castera; Mona Munteanu; Françoise Imbert-Bismut; Vlad Ratziu; Yves Benhamou; Marc Bourlière; Victor de Ledinghen
Standardization of ROC curve areas for diagnostic evaluation of liver fibrosis markers based on prevalences of fibrosis stages.
Clinical chemistry 2007;53(9):1615-22.
2007: Patrick Marcellin; Marc Bourlière; Jean-Michel Pawlotsky; Denis Ouzan
[HCV non-responder patients: definition of non-response and treatment strategy].
Gastroentérologie clinique et biologique 2007;31(8-9 Pt 3):4S13-9.
2007: Christophe Renou; Jean-Francois Cadranel; Marc Bourlière; Philippe Halfon; Denis Ouzan; Hervè Rifflet; Philippe Carenco; Abdelouahid Harafa; Jean-Jacques Bertrand; Annie Boutrouille; Pierre Muller; Jean-Pierre Igual; Anne Decoppet; Marc Eloit; Nicole Pavio
Possible zoonotic transmission of hepatitis E from pet pig to its owner.
Emerging infectious diseases 2007;13(7):1094-6.
2007: Dominique Roulot; V Bourcier; Véronique Grando; Paul Deny; Y Baazia; H Fontaine; F Bailly; Laurent Castera; Victor de Ledinghen; P Marcellin; Raoul Poupon; Marc Bourlière; J P Zarski; F Roudot-Thoraval
Epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection.
Journal of viral hepatitis 2007;14(7):460-7.
2007: Rami Moucari; Marie-Pierre Ripault; Valérie Oulès; Michèle Martinot-Peignoux; Tarik Asselah; Nathalie Boyer; Ahmed El Ray; Dominique Cazals-Hatem; Dominique Vidaud; Dominique Valla; Marc Bourlière; Patrick Marcellin
High predictive value of early viral kinetics in retreatment with peginterferon and ribavirin of chronic hepatitis C patients non-responders to standard combination therapy.
Journal of hepatology 2007;46(4):596-604.
2007: Thierry Poynard; P Halfon; Laurent Castera; Frédéric Charlotte; Brigitte Le Bail; Mona Munteanu; Djamila Messous; Vlad Ratziu; Yves Benhamou; Marc Bourlière; Victor de Ledinghen
Variability of the area under the receiver operating characteristic curves in the diagnostic evaluation of liver fibrosis markers: impact of biopsy length and fragmentation.
Alimentary pharmacology & therapeutics 2007;25(6):733-9.
2007: Philippe Halfon; Marc Bourlière; Guillaume Pénaranda; Patrice Cacoub
[Noninvasive methods for predicting liver fibrosis in patients with chronic hepatitis C: alternatives to liver biopsy].
Presse médicale (Paris, France : 1983) 2007;36(3 Pt 2):457-66.
2007: Jean-François Cadranel; Jean-Louis Boujenah; Marc Bourlière; Thierry Fontanges; Stanislas Pol; Christian Trepo; Denis Ouzan
Satisfaction of patients treated for chronic hepatitis C with the peginterferon alfa-2b pen device: the VISA observational study.
Gastroentérologie clinique et biologique 2007;31(2):180-4.
2006: Michal Abel; Damien Sène; Stanislas Pol; Marc Bourlière; Thierry Poynard; Frédéric Charlotte; Patrice Cacoub; Sophie Caillat-Zucman
Intrahepatic virus-specific IL-10-producing CD8 T cells prevent liver damage during chronic hepatitis C virus infection.
Hepatology (Baltimore, Md.) 2006;44(6):1607-16.
2006: Marc Bourlière
[Future perspectives and strategies in managing resistance to analogue antiviral drugs in the treatment of chronic hepatitis B].
Gastroentérologie clinique et biologique 2006;30(10 Pt 2):3S34-6.
2006: Jean-Pierre Bronowicki; Denis Ouzan; Tarik Asselah; Hervé Desmorat; Jean-Pierre Zarski; Juliette Foucher; Marc Bourlière; Christophe Renou; Albert Tran; Pascal Melin; Christophe Hézode; Michelle Chevalier; Magali Bouvier-Alias; Stéphane Chevaliez; François Montestruc; Isabelle Lonjon-Domanec; Jean-Michel Pawlotsky
Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.
Gastroenterology 2006;131(4):1040-8.
2006: Philippe Halfon; Marc Bourlière; Guillaume Pénaranda; Patrice Cacoub
[Serum markers of non-invasive fibrosis in chronic hepatitis C virus infection].
La Revue de médecine interne / fondée ... par la Société nationale francaise de médecine interne 2006;27(10):751-61.
2006: Corinne Bonny; H Fontaine; T Poynard; Christophe Hézode; D Larrey; P Marcellin; Marc Bourlière; Jean-Pierre Bronowicki; P Merle; J P Zarski; T Sapey; C Guillemard; Sylvie Ughetto; Cécile Henquell; C Nicolas; C Roche; K Randl; Gilles Bommelaer; Armand Abergel
Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study.
Alimentary pharmacology & therapeutics 2006;24(4):593-600.
2006: Philippe Halfon; Marc Bourlière; Guillaume Pénaranda; Hacène Khiri; Denis Ouzan
Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection.
Journal of clinical microbiology 2006;44(7):2507-11.
2006: Philippe Halfon; Marc Bourlière; S Pol; Y Benhamou; Denis Ouzan; Michel Rotily; Hacène Khiri; Christophe Renou; Guillaume Pénaranda; David Saadoun; Vincent Thibault; J Serpaggi; M Varastet; Marie-Hélène Tainturier; Thierry Poynard; Patrice Cacoub
Multicentre study of hepatitis B virus genotypes in France: correlation with liver fibrosis and hepatitis B e antigen status.
Journal of viral hepatitis 2006;13(5):329-35.
2006: Souad Benali; Christian Boustière; Paul Castellani; Christine Cesari; Monique Jullien; Laurence Lecomte; Olivier Lebars; Gérard Lambot; Robert Loyer; Amina Masseboeuf; Hervé Perrier; Valérie Oules; Marc Bourlière
[Sarcoidosis following pegylated interferon therapy: two cases].
Gastroentérologie clinique et biologique 2006;30(4):615-9.
2006: Christophe Renou; Marc Bourlière; François Martini; Denis Ouzan; Guillaume Penaranda; Olivier Larroque; Abdelouahid Harafa; Jean-Pierre Igual; Bernard Calvet; Serge Sokolowsky; Thierry Benderitter; Philippe Halfon
Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: complete biochemical and histological response to therapy with ursodesoxycholic acid.
Journal of gastroenterology and hepatology 2006;21(4):781-2.
2006: Philippe Halfon; Guillaume Pénaranda; Marc Bourlière; Hacène Khiri; Marie-France Masseyeff; Denis Ouzan
Assessment of early virological response to antiviral therapy by comparing four assays for HCV RNA quantitation using the international unit standard: implications for clinical management of patients with chronic hepatitis C virus infection.
Journal of medical virology 2006;78(2):208-15.
2006: Philippe Halfon; Claude Giorgetti; Marc Bourlière; Véronique Chabert-Orsoni; Hacène Khiri; Guillaume Pénaranda; Jean-Marc Chincholle; Hervé Gallais; Isabelle Ravaux; Jacques Moreau; Jean-Albert Gastaud; Roger Roulier
Medically assisted procreation and transmission of hepatitis C virus: absence of HCV RNA in purified sperm fraction in HIV co-infected patients.
AIDS (London, England) 2006;20(2):241-6.
2006: Stanislas Pol; Marc Bourlière
Optimizing treatment outcomes in chronic hepatitis C: management of non-response.
Antiviral therapy 2006;11(8):955-70.
2005: Patrice Cacoub; David Saadoun; Marc Bourlière; Hacène Khiri; Agnes Martineau; Yves Benhamou; Marina Varastet; Stanislas Pol; Vincent Thibault; Michel Rotily; Philippe Halfon
Hepatitis B virus genotypes and extrahepatic manifestations.
Journal of hepatology 2005;43(5):764-70.
2005: Philippe Halfon; Marc Bourlière; Guillaume Pénaranda; Romaric Deydier; Christophe Renou; Danielle Botta-Fridlund; Albert Tran; Isabelle Portal; Isabelle Allemand; Alessandra Rosenthal-Allieri; Denis Ouzan
Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus.
Comparative hepatology 2005;4():6.
2005: Marc Bourlière
[Inactive carrier of hepatitis B virus].
Gastroentérologie clinique et biologique 2005;29(4):369-73.
2003: P Halfon; A U Neumann; Marc Bourlière; Alain Rieu; Stéphane Chadapaud; Hacène Khiri; Denis Ouzan; P Cacoub
Slow viral dynamics of hepatitis C virus genotype 4.
Journal of viral hepatitis 2003;10(5):351-3.
2003: Marc Bourlière
[Transmission of hepatitis B and C viruses from caregiver to patients: myths and reality].
Gastroentérologie clinique et biologique 2003;27(3 Pt 1):291-3.
2003: P Cacoub; Marc Bourlière; Pierre Hausfater; Frédéric Charlotte; Hacène Khiri; S Toci; J C Piette; T Poynard; P Halfon
Lower expression of CD81 B-cell receptor in lymphoproliferative diseases associated with hepatitis C virus infection.
Journal of viral hepatitis 2003;10(1):10-5.
2002: Philippe Halfon; Stanislas Pol; Marc Bourlière; Patrice Cacoub
[Hepatitis B virus genotypes: clinical, epidemiological and therapeutic implications].
Gastroentérologie clinique et biologique 2002;26(11):1005-12.
2002: Philippe Halfon; Marc Bourlière; Hacène Khiri; Gilles Halimi; Victoria Gerolami; JM Feryn; Denis Ouzan
Serological response to infection with different isolates of hepatitis C virus.
Journal of viral hepatitis 2002;9(6):438-42.
2002: Jean-Baptiste Nousbaum; Jean-François Cadranel; Georges Bonnemaison; Marc Bourlière; Laurence Chiche; Hélène Chor; Marie-Hélène Denninger; Françoise Degos; Emmanuel Jacquemin; Brigitte Le Bail; Véronique Loustaud-Ratti; Gilles Pelletier; PHILIPPE SOYER; Marc Zins
[Clinical practice guidelines on the use of liver biopsy].
Gastroentérologie clinique et biologique 2002;26(10):848-78.
2002: Victor de Lédinghen; Pascale Trimoulet; Maria Winnock; Pierre-Henri Bernard; Marc Bourlière; Isabelle Portal; André-Jean Rémy; Nathalie Szostak; Stéphane Lévy; Albert Tran; Armand Abergel; Geneviève Chêne; Hervé Fleury; Patrice Couzigou
Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.
Journal of hepatology 2002;36(6):819-26.
2002: Victor de Lédinghen; Pascale Trimoulet; Maria Winnock; Juliette Foucher; Marc Bourlière; Hervé Desmorat; Valérie Canva; Dominique Capron; Stéphane Lévy; François Mion; Paul-Régis Mannant; Geneviève Chêne; Hervé Fleury; Patrice Couzigou; Pierre-Henri Bernard
Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.
Journal of hepatology 2002;36(5):672-80.
2002: Marc Bourlière; Philippe Halfon; Isabelle Portal
[Treatment of chronic hepatitis C in special groups].
Gastroentérologie clinique et biologique 2002;26 Spec No 2():B238-47.
2002: Marc Bourlière; J M Barberin; Michel Rotily; Valérie Guagliardo; Isabelle Portal; Laurence Lecomte; Souad Benali; Christian Boustière; Hervé Perrier; Monique Jullien; Gérard Lambot; R Loyer; O LeBars; R Daniel; Hacène Khiri; Philippe Halfon
Epidemiological changes in hepatitis C virus genotypes in France: evidence in intravenous drug users.
Journal of viral hepatitis 2002;9(1):62-70.
2001: Françoise Roudot-Thoraval; Armand Abergel; francois allaert; Marc Bourlière; Hervé Desmorat; F Fagnani; Thierry Fontanges; A Hanana; S Pol; Jean-Pierre Zarski; C Rousseaux; C Gandossi; L Samelson; S Dole; S Dantin; F Eberlé; MF Saint-Marc-Girardin; L Abelsour
[Hepavir, the first observational study of one cohort of patients treated with alpha-2a interferon, monotherapy. Evaluation of asthenia and its social consequences].
Gastroentérologie clinique et biologique 2001;25(12):1061-6.
2001: Marc Bourlière; V Oulés; Hervé Perrier; C Mengotti
Onset of coeliac disease and interferon treatment.
Lancet 2001;357(9258):803-4.
2000: Philippe Halfon; Gilles Halimi; Marc Bourlière; Denis Ouzan; Jacques Durant; Hacène Khiri; Laurence Mercier; Victoria Gerolami; G Cartouzou
Integrity of the NS5A (amino acid 2209 to 2248) region in hepatitis C virus 1b patients non-responsive to interferon therapy.
Liver 2000;20(5):381-6.
2000: Marc Bourlière; Philippe Halfon; Yves Quentin; P David; C Mengotti; Isabelle Portal; Hacène Khiri; Souad Benali; Hervé Perrier; Christian Boustière; Monique Jullien; Gérard Lambot
Covert transmission of hepatitis C virus during bloody fisticuffs.
Gastroenterology 2000;119(2):507-11.
2000: Stanislas Pol; Bertrand Nalpas; Marc Bourlière; Patrice Couzigou; Agnès Tran; Armand Abergel; J P Zarski; P Berthelot; Christian Bréchot
Combination of ribavirin and interferon-alfa surpasses high doses of interferon-alfa alone in patients with genotype-1b-related chronic hepatitis C.
Hepatology (Baltimore, Md.) 2000;31(6):1338-44.
1999: G Babany; Marc Bourlière; H Chevalier; M Chousterman; Patrice Couzigou; Hervé Desmorat; Daniel Dhumeaux; M Doffoël; J Gournay; D Loiseau; Philippe Mercet; Joseph Moussalli; C Trépo; G Tucat; D Doan Tran; MF Saint-Marc-Girardin
[Do general practitioners want to manage chronic hepatitis C and take part in hepatitis C health networks? A national survey].
Gastroentérologie clinique et biologique 1999;23(12):1289-95.
1999: Stanislas Pol; Patrice Couzigou; Marc Bourlière; Armand Abergel; J M Combis; D Larrey; Agnès Tran; Joseph Moussalli; Raoul Poupon; P Berthelot; Christian Bréchot
A randomized trial of ribavirin and interferon-alpha vs. interferon-alpha alone in patients with chronic hepatitis C who were non-responders to a previous treatment. Multicenter Study Group under the coordination of the Necker Hospital, Paris, France.
Journal of hepatology 1999;31(1):1-7.
1999: Philippe Halfon; Yves Quentin; Bertrand Roquelaure; Jacques Sarles; Gilles Halimi; Victoria Gerolami; Hacène Khiri; Marc Bourlière; G Cartouzou
Mother-to-infant transmission of hepatitis C virus: molecular evidence of superinfection by homologous virus in children.
Journal of hepatology 1999;30(6):970-8.
1998: Philippe Halfon; Marc Bourlière; Gilles Halimi; Hacène Khiri; P Bertezene; Isabelle Portal; Danielle Botta-Fridlund; A P Gauthier; Monique Jullien; JM Feryn; Victoria Gerolami; G Cartouzou
Assessment of spontaneous fluctuations of viral load in untreated patients with chronic hepatitis C by two standardized quantitation methods: branched DNA and Amplicor Monitor.
Journal of clinical microbiology 1998;36(7):2073-5.
1997: Michel Rotily; C Vernay-Vaisse; Marc Bourlière; A Galinier-Pujol; S Rousseau; Yolande Obadia
HBV and HIV screening, and hepatitis B immunization programme in the prison of Marseille, France.
International journal of STD & AIDS 1997;8(12):753-9.
1997: Michel Rotily; C Vernay-Vaisse; Marc Bourlière
Three quarters of one French prison population needed immunisation against hepatitis B.
BMJ (Clinical research ed.) 1997;315(7099):61.
1997: Michel Rotily; Sandrine Loubière; J Nixon; Marc Bourlière; P Halfon; Jean-Paul Moatti
[Should hepatitis C be screened? Socioeconomic analysis of different screening strategies for chronic hepatitis C in French population].
Gastroentérologie clinique et biologique 1997;21(1 Pt 2):S33-40.
1994: D Valla; G Babany; D Ouzan; C Trépo; Marc Bourlière; P Calès; J L Payen; P Couzigou; C Buffet; P Michel
Prevention of relapse in patients with chronic non-A, non-B/C hepatitis who respond to alpha-interferon. A controlled multicenter trial of low-dose maintenance therapy. Groupe d'Etude Multicentrique de l'Interféron dans les Hépatites.
Journal of hepatology 1994;21(5):774-8.
1991: Marc Bourlière; B Pol; M Antoni; A Maillot; Danielle Botta-Fridlund; Yves Patrice Le Treut; A P Gauthier
LeVeen shunt with wandering tip.
Lancet 1991;338(8773):1012.
1991: M Antoni; Marc Bourlière; J Toullec; A Maillot; Danielle Botta-Fridlund; A Gauthier
[Fatal subfulminant hepatitis caused by cyproterone acetate].
Gastroentérologie clinique et biologique 1991;15(10):772-3.
1990: Marc Bourlière; Yves Patrice Le Treut; D Arnoux; Paul Castellani; L Bordigoni; A Maillot; M Antoni; D Botta; B Pol; A P Gauthier
Acute Budd-Chiari syndrome with hepatic failure and obstruction of the inferior vena cava as presenting manifestations of hereditary protein C deficiency.
Gut 1990;31(8):949-52.
1990: M Antoni; Danielle Botta-Fridlund; Marc Bourlière; H Bun; A P Gauthier
[Benzodiazepines and liver diseases. Pharmacokinetics and pharmacodynamic effects].
Gastroentérologie clinique et biologique 1990;14(5):492-500.